Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Agonist-induced phosphorylation of G protein-coupled receptors (GPCRs) is a primary determinant of β-arrestin (βarr) recruitment and trafficking. For several GPCRs such as the vasopressin receptor subtype 2 (VR), agonist-stimulation first drives the translocation of βarrs to the plasma membrane, followed by endosomal trafficking, which is generally considered to be orchestrated by multiple phosphorylation sites. We have previously shown that mutation of a single phosphorylation site in the VR (i.e., VR) results in near-complete loss of βarr translocation to endosomes despite robust recruitment to the plasma membrane, and compromised ERK1/2 activation. Here, we discover that a synthetic intrabody (Ib30), which selectively recognizes activated βarr1, efficiently rescues the endosomal trafficking of βarr1 and ERK1/2 activation for VR. Molecular dynamics simulations reveal that Ib30 enriches active-like βarr1 conformation with respect to the inter-domain rotation, and cellular assays demonstrate that it also enhances βarr1-β-adaptin interaction. Our data provide an experimental framework to positively modulate the receptor-transducer-effector axis for GPCRs using intrabodies, which can be potentially integrated in the paradigm of GPCR-targeted drug discovery.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360436PMC
http://dx.doi.org/10.1038/s41467-022-32386-xDOI Listing

Publication Analysis

Top Keywords

synthetic intrabody
8
plasma membrane
8
endosomal trafficking
8
erk1/2 activation
8
allosteric modulation
4
modulation gpcr-induced
4
gpcr-induced β-arrestin
4
trafficking
4
β-arrestin trafficking
4
trafficking signaling
4

Similar Publications

Development of mRNA-lipid nanoparticle intrabodies against rickettsial infection.

J Biomed Sci

August 2025

Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, 1925 Coffey Road, Columbus, OH, 43210, USA.

Background: Rickettsiosis is among the deadliest vector-borne infectious diseases worldwide, in part because rickettsiae replicate within human cells, where antibodies and most drugs cannot effectively reach this obligatory intracellular pathogen. Ehrlichia chaffeensis, an emerging rickettsia, is the causative agent of human monocytic ehrlichiosis. We therefore aim to generate intrabodies (IBs), the variable domain of heavy chain of heavy-chain-only antibodies (VHHs) that bind intracellular bacterial proteins to inhibit E.

View Article and Find Full Text PDF

Subcellular compartmentalization is integral to the spatial regulation of mechanistic target of rapamycin (mTOR) signaling. However, the biological outputs associated with location-specific mTOR signaling events are poorly understood and challenging to decouple. Here, we engineered synthetic intracellular antibodies (intrabodies) that are capable of modulating mTOR signaling with genetically programmable spatial resolution.

View Article and Find Full Text PDF

We explore the capabilities of a microfluidic-based synthetic molecular communication (SMC) system for the transmission of physiological data within the human body. The system employs oscillating water droplets as a means of transmitting information through pressure variations. The validity of this approach for binary communications is validated through a combination of simulations and experiments.

View Article and Find Full Text PDF

Recombinant antibodies and, more recently, T cell receptor (TCR)-engineered T cell therapies represent two immunological strategies that have come to the forefront of clinical interest for targeting intracellular neoantigens in benign and malignant diseases. T cell-based therapies targeting neoantigens use T cells expressing a recombinant complete TCR (TCR-T cell), a chimeric antigen receptor (CAR) with the variable domains of a neoepitope-reactive TCR as a binding domain (TCR-CAR-T cell) or a TCR-like antibody as a binding domain (TCR-like CAR-T cell). Furthermore, the synthetic T cell receptor and antigen receptor (STAR) and heterodimeric TCR-like CAR (T-CAR) are designed as a double-chain TCRαβ-based receptor with variable regions of immunoglobulin heavy and light chains (VH and VL) fused to TCR-Cα and TCR-Cβ, respectively, resulting in TCR signaling.

View Article and Find Full Text PDF
Article Synopsis
  • Monoclonal antibodies, like lecanemab and aducanumab, have been recently approved in the USA as treatments for Alzheimer's disease, although they are costly and require frequent administration.
  • Researchers are exploring synthetic messenger RNA (mRNA) as a new method to produce antibodies, potentially addressing the limitations of traditional antibody production.
  • This study successfully created synthetic mRNA for a tau-specific antibody, demonstrating its effectiveness in producing functioning antibodies and targeting intracellular tau, which could benefit Alzheimer's and related diseases.
View Article and Find Full Text PDF